COMP <GO>
CVS vs WMT // FORWARD P/E MULTIPLE
CVS Health Corporation (NYSE) VS. Walmart Inc. (NYSE) • 15-METRIC TALLY: CVS 5
— WMT 9
▲ FORWARD P/E MULTIPLE LEADER: WMT
LAST: $90.25 (-0.09%) • MKT CAP: $115.53B
forward-pe
60.7x
LAST: $123.51 (+1.86%) • MKT CAP: $972.82B
forward-pe
35.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CVS VS. WMT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CVS | WMT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.00% | 25.23% | +19.77 | CVS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.60% | 20.14% | -17.54 | WMT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.7x | 22.5x | +3.20 | WMT | /valuation <GO> |
| Free Cash Flow Yield | 6.76% | 1.39% | +5.37 | CVS | /fcf-yield <GO> |
| Operating Margin | 1.20% | 4.39% | -3.19 | WMT | /operating-margins <GO> |
| Net Profit Margin | 0.40% | 3.00% | -2.60 | WMT | /net-margins <GO> |
| Revenue Growth (YoY) | 7.80% | 6.16% | +1.64 | CVS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.94% | 0.80% | +2.14 | CVS | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.31 | 6.23 | -3.92 | WMT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.38% | +0.12 | WMT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.5 | 72.7 | -25.22 | WMT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.57 | +0.31 | CVS | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 60.7x | 35.5x | +25.20 | WMT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $115.53B | $972.82B | -$857.30B | WMT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CVS REV | WMT REV | CVS GROSS % | WMT GROSS % | CVS FCF | WMT FCF |
|---|---|---|---|---|---|---|
| FY 2026 | — | $713.16B | — | 24.9% | — | $14.92B |
| FY 2025 | $402.07B | $680.99B | 45.0% | 24.9% | $7.81B | $12.66B |
| FY 2024 | $372.81B | $648.13B | 44.7% | 24.4% | $6.33B | $15.12B |
| FY 2023 | $357.78B | $611.29B | 44.0% | 24.1% | -$2.67B | $11.98B |
| FY 2022 | — | $572.75B | — | 25.1% | — | $11.07B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CVS // BETA 0.88
WMT // BETA 0.57